GP2015依那西普生物类似药治疗中重度类风湿关节炎的24周III期EQUIRA研究
EQUIRA研究将376例对合成或生物DMARDs应答不足的中重度活动性RA患者按1:1随机分配至GP2015或参照依那西普50mg皮下每周一次治疗24周,同时联用稳定剂量甲氨蝶呤10-25mg/周。结果显示两组DAS28-CRP自基线变化的最小二乘均数差为-0.07(95%CI -0.26至0.12),落在预设等效界值-0.6至0.6内,证实疗效等效,安全性与免疫原性相当。
要点
- GP2015与参照依那西普24周DAS28-CRP变化差值为-0.07,95%CI在等效界值内
- 治疗中出现的不良事件发生率GP2015组43.5%、参照依那西普组49.5%
- GP2015组未出现中和性抗药抗体,参照依那西普组第4周1.6%、第12周0.6%阳性
核心结论
- 在中重度活动性RA且对DMARDs应答不足的患者中,GP2015与参照依那西普疗效相似,安全性和免疫原性相当。
研究设计与样本
- EQUIRA为比较性III期随机双盲研究,纳入376例患者,1:1随机接受GP2015或参照依那西普50mg皮下每周一次治疗24周,并联用稳定剂量甲氨蝶呤10-25mg/周。
主要发现
- DAS28-CRP自基线至第24周变化的最小二乘均数差(GP2015减参照依那西普)为-0.07(95%CI -0.26至0.12),为主要终点。
- 治疗中出现的不良事件发生率GP2015组为43.5%,参照依那西普组为49.5%。
- GP2015组无患者产生中和性抗药抗体;参照依那西普组第4周1.6%、第12周0.6%患者中和性抗药抗体阳性。
关键数值与推荐
- 等效性判定标准为两组DAS28-CRP自基线至第24周变化差的95%CI落在预设等效界值-0.6至0.6范围内。
临床怎么用
- 结果支持GP2015作为参照依那西普的生物类似药用于对DMARDs应答不足的中重度活动性RA患者。
局限性
- 本文仅报告24周结果,长期疗效、安全性和免疫原性未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To demonstrate the equivalent efficacy and compare the safety and immunogenicity of an etanercept biosimilar, GP2015, with reference etanercept (ETN) in patients with moderate-to-severe, active rheumatoid arthritis (RA), characterised by an inadequate response to synthetic or biologic disease-modifying antirheumatic drugs (DMARDs). METHODS: In the EQUIRA study, eligible patients (n=376) were randomised 1: 1 to 50 mg GP2015 or ETN subcutaneously, once weekly, for 24 weeks (treatment period 1). Patients from both groups, with at least moderate European League Against Rheumatism response at week 24, received GP2015 up to week 48 (treatment period 2). All patients continued to receive concomitant methotrexate at a stable dose (10-25 mg/week) until end of the study. The 24-week results are presented here. RESULTS: Equivalent efficacy between GP2015 and ETN was demonstrated if the 95% CI for the difference in disease activity score 28-joint count C reactive protein (DAS28-CRP) change from baseline to week 24 between treatment arms was contained within the prespecified equivalence margin range of -0.6 to 0.6. The least squares mean difference (GP2015-ETN) in change from baseline in DAS28-CRP up to week 24 was -0.07 (95% CI -0.26 to 0.12 [primary endpoint)]. The incidence of treatment-emergent adverse events was comparable between GP2015 (43.5%) and ETN (49.5%). None of the GP2015-treated patients developed neutralising anti-drug antibodies (NAbs) whereas 1.6% and 0.6% of patients in ETN group were NAb positive at weeks 4 and 12, respectively. CONCLUSION: In patients with RA who had an inadequate response to DMARDs, GP2015 demonstrated a similar efficacy and a comparable safety and immunogenicity profile with ETN. TRIAL REGISTRATION: NCT02638259.
引用
- Matucci-Cerinic M, Allanore Y, Kavanaugh A, et al. Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. RMD Open. 2018. PMID: 30487998. doi:10.1136/rmdopen-2018-000757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。